Pancreatic Cancer Research

ResearcherJiangnan UniversityActive in the last 2 years

Leisheng Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0002-3280-9587; OpenAlex author ID A5066021709. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: 2 papers

Papers 3

  1. NAT10 regulates tumor progression and immune microenvironment in pancreatic ductal adenocarcinoma via the N4-acetylated LAMB3-mediated FAK/ERK pathway. Co-author DOI 10.1002/cac2.70045↗
  2. Targeting the ac4C 'Writer' NAT10 enhances pancreatic cancer immunotherapy via dual modulation of CD8+ T cells and tumor cells. Co-author DOI 10.1038/s41419-025-08156-0↗
  3. The DEAD-box RNA helicase, DDX60, Suppresses immunotherapy and promotes malignant progression of pancreatic cancer. Co-author DOI 10.1016/j.bbrep.2023.101488↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shuo Zhang · 3 shared papers, 2023–2025 · strength 0.64
  2. Enhong Chen · 2 shared papers, 2025 · strength 0.45
  3. Hao Hu · 2 shared papers, 2025 · strength 0.45
  4. Shudong Hu · 1 shared paper, 2025 · strength 0.22
  5. Hao Ye · 1 shared paper, 2025 · strength 0.22
  6. Tiantian Lai · 1 shared paper, 2023 · strength 0.19
  7. Hao Hu · 1 shared paper, 2023 · strength 0.19
  8. Xiaowen Su · 1 shared paper, 2023 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.